📢 New Earnings In! 🔍
Dafinchi
Thermo Fisher Scientific Inc.
TMO
2025 Q2Healthcare
2d
Strategic Long-Term Growth Outlook at 7% Plus
- Management articulated a long-term organic revenue growth target of 7% plus, driven by industry fundamentals and share gains.
- The 7% plus growth rate is based on a base market growth of around 4%, with an additional 2-3 points from share gains.
- Management emphasized confidence in industry drivers such as scientific breakthroughs and unmet medical needs, despite macroeconomic uncertainties.
Boston Scientific Corporation
BSX
2025 Q2Healthcare
2d
Exceptional Second Quarter Growth and Outperformance
- Total company operational sales grew 22%, organic sales grew 17%, exceeding guidance of 13-15%.
- Second quarter adjusted EPS of $0.75 increased 23%, surpassing guidance of $0.71-$0.73.
- Strong momentum driven by Cardiovascular segment, especially in the U.S. and Asia Pacific.
Intuitive Surgical, Inc.
ISRG
2025 Q2Healthcare
2d
Launch and Adoption of da Vinci 5 Platform in Key Markets
- Broad launch of da Vinci 5 in the U.S. with over 100,000 procedures performed to date.
- Received clearances in Europe and Japan, with measured launches planned.
- Focus on building infrastructure, training, and customer engagement for regional rollouts.
- Early adopters in Europe and Japan expected to respond to new technology, with some customers waiting for specific features like force feedback.
Danaher Corporation
DHR
2025 Q2Healthcare
3d
Danaher CFO Succession Plan and Leadership Transition
- Announcement of Matt Gugino succeeding Matt McGrew as CFO at the end of February 2026.
- Matt McGrew to continue as EVP and begin gradual retirement.
- Recognition of Matt McGrew's leadership in pivotal moments including Vista, Baralso, and Sytiva acquisition.
- Matt Gugino's extensive experience in investor relations, FP&A, M&A, and operational roles, positioning him as a strong future CFO.
Impact and Management of PAMA Legislation for 2026
- The company anticipates a potential $100 million impact if PAMA is implemented next year, with ongoing efforts to delay or mitigate this through legislation and data collection improvements.
- Management is working with trade organizations to seek legislative solutions, including delays and data adjustments, to offset the impact.
- Base case assumption is that PAMA will come into effect in 2026, but the company is preparing for various scenarios, including offsets via initiatives like LaunchPad.
1d
Rapid Growth and Market Adoption of GLP-1 Elastomer Products
- GLP-1 elastomer products accounted for 8% of total company revenues in Q2 2025, up from 7% last quarter.
- Demand driven by a large customer ramping production, supporting the company's ability to respond to increased customer demand.
- Management expects continued strong growth in GLP-1 products throughout 2025, contributing significantly to HVP components growth.
- The company leverages pandemic-era investments to meet the demand for GLP-1 elastomers, indicating strategic capacity utilization.
Molina Healthcare, Inc.
MOH
2025 Q2Healthcare
1d
Unprecedented Medical Cost Trends and Impact on Margins
- The second quarter 2025 medical cost ratio (MCR) was 90.4%, reflecting an unprecedented environment of rising medical costs across Medicaid, Medicare, and Marketplace segments.
- Cost pressures are driven by behavioral health, high-cost drugs, inpatient and outpatient care, with trends surpassing rate updates and risk corridor protections.
- Management emphasizes the effectiveness of cost control protocols despite the higher intake volumes and persistent cost increases.
IQVIA Holdings Inc.
IQV
2025 Q2Healthcare
3d
AI Agentification and Strategic Collaboration with NVIDIA
- IQVIA is developing over 50 AI agents covering clinical, commercial, and R&DS use cases, with more than 20 agents already in production.
- The collaboration with NVIDIA supports training and deployment of AI agents, with positive client interest and early success in reducing process times and increasing review capacity.
- AI initiatives are expected to significantly enhance operational efficiency, speed of project execution, and long-term margin expansion.
Quest Diagnostics Incorporated
DGX
2025 Q2Healthcare
3d
Impact of US Healthcare Policy Changes and Uninsured Population on Quest Diagnostics
- Management assesses the potential impact of the 'One Big Beautiful Bill' on Quest Diagnostics, estimating a maximum 30-40 basis point volume impact in 2026 due to increased uninsured individuals.
- They highlight that the bill reduces US healthcare spending by approximately 1.5% of the total $5 trillion annual healthcare expenditure, with minimal immediate impact on Medicaid and exchange-based revenues.
- Management emphasizes that most exchange enrollees are employed and have incomes, thus likely to maintain insurance coverage or pay higher premiums, mitigating volume loss.
Tenet Healthcare Corporation
THC
2025 Q2Healthcare
3d
Impact of Proposed Outpatient Hospital Care Rule and Inpatient-Only Rule Elimination
- Management views the potential removal of the inpatient-only rule as positive for USPI, enabling more outpatient procedures, but emphasizes the need for clinical expertise and patient selection.
- The move is seen as an opportunity for growth, with the company well-positioned due to its advanced ASC capabilities.
- Uncertainty remains around regulatory implementation and the broader impact on hospital and ASC business models.
Elevance Health Inc.
ELV
2025 Q2Healthcare
1w
Revised Full-Year Guidance and Strategic Response to Cost Trends
- Elevance Health revised its 2025 adjusted EPS guidance to approximately $30, citing industry-wide increased morbidity and slower Medicaid rate adjustments.
- Management emphasized actions to stabilize trends, improve pricing, and reinforce operational foundations, including cost management and targeted investments.
- The company is focusing on long-term margin stability through initiatives in specialty services, post-acute care, and outpatient settings, with a strategic emphasis on Carelon platform expansion.
Medpace Holdings, Inc.
MEDP
2025 Q2Healthcare
3d
Strong RFP Flow and Decision Rate Indicating Potential Book-to-Bill Rebound
- RFP flow in Q2 remained strong with an increase in decision-making rate.
- Pending RFP dollars were down, but award notifications were high, leading to a book-to-bill of 1.03x.
- Management expects book-to-bill to return above 1.15x in Q3, signaling a potential rebound in bookings.
2d
Genesis HealthCare Bankruptcy and Its Impact on Business Strategy
- Genesis filed for Chapter 11 bankruptcy on July 9, 2025.
- Healthcare Services Group continued contractual relationships with Genesis facilities without disruption.
- Management views the bankruptcy as specific to Genesis and not reflective of industry health.
- The event is expected to lead to stronger, healthier client facilities and provide balance sheet clarity.
- The company is reserving its exposure and expects to fully reserve its receivables by the end of Q3, with recovery prospects still uncertain.
Thermo Fisher Scientific Inc.
TMO
2025 Q2Healthcare
2d
Revenue Beat
+3%
$10.85 billion
Our revenue in the quarter grew 3% to $10.85 billion... These results were ahead of our guidance.
Thermo Fisher Scientific Inc.
TMO
2025 Q2Healthcare
2d
Financial Performance Summary
- Free cash flow was $1.5 billion after $645 million in capital expenditures; ended quarter with $6.4 billion cash and $35.2 billion debt.
- Leverage ratio was 3.2x gross debt to adjusted EBITDA and 2.7x net debt to EBITDA.
- Adjusted ROIC was 11.3%, reflecting strong returns on investment.
- Tariffs and FX negatively impacted margins by 140 basis points, partially offset by productivity gains.
- Segment performance: Life Sciences Solutions revenue up 6% with 4% organic growth; Analytical Instruments revenue declined 3% with 4% organic decline; Specialty Diagnostics revenue grew 2% with flat organic growth; Laboratory Products and Biopharma Services revenue increased 4% with 3% organic growth.
- Organic revenue growth was 2%, with a 1% contribution from acquisitions and a 1% FX tailwind.
- Adjusted EPS was $5.36, beating guidance, with GAAP EPS at $4.28, up 6% year-over-year.
- Q2 revenue grew 3% to $10.85 billion, adjusted operating income grew 1% to $2.38 billion, with an adjusted operating margin of 21.9%.
- Adjusted gross margin was 41.3%, down 80 basis points year-over-year due to tariffs and FX.
- Organic revenue growth was 2%, with a 1% contribution from acquisitions and a 1% FX tailwind.
- Q2 revenue grew 3% to $10.85 billion, adjusted operating income increased 1% to $2.38 billion, with an adjusted operating margin of 21.9%.
- Adjusted EPS was $5.36, beating guidance, with GAAP EPS at $4.28, up 6% year-over-year.
- Segment performance varied: Life Sciences Solutions grew 6% reported and 4% organic; Analytical Instruments revenue declined 3%; Specialty Diagnostics grew 2%; Laboratory Products and Biopharma Services grew 4%.
- Adjusted SG&A was 16.2% of revenue; R&D expense was $352 million (7.4% of manufacturing revenue).
- Tariffs and FX negatively impacted margins by 140 basis points, partially offset by productivity gains.
- Adjusted ROIC was 11.3%, reflecting strong returns on investment.
- Free cash flow was $1.5 billion after $645 million in capital expenditures; leverage ratio was 3.2x gross debt to adjusted EBITDA.
Boston Scientific Corporation
BSX
2025 Q2Healthcare
2d
Revenue Beat
+7%
22% operational sales growth
In second quarter '25, total company operational sales grew 22% and organic sales grew 17%, which exceeds the high end of our guidance range of 13% to 15% and far outpacing our underlying weighted average market growth rate.
Boston Scientific Corporation
BSX
2025 Q2Healthcare
2d
Financial Performance Summary
- Adjusted gross margin was 69.4%, down 100 basis points due to inventory charges from ACURATE discontinuation.
- Cash on hand was $534 million as of June 30, 2025.
- Credit rating upgraded to A3 by Moody's, now holding A- equivalent ratings from all major agencies.
- Second quarter 2025 total company operational sales grew 22%, organic sales grew 17%, exceeding guidance of 13% to 15%.
- Adjusted EPS was $0.75, up 23%, exceeding guidance of $0.71 to $0.73, including charges related to ACURATE valve discontinuation.
- Adjusted operating margin was 27.6%, expanding 50 basis points year-over-year.
- Second quarter consolidated revenue was $5.061 billion, representing 22.8% reported growth versus Q2 2024.
- Organic revenue growth was 17.4%, exceeding guidance.
- Free cash flow was $1.129 billion for Q2, with full year 2025 free cash flow expected at approximately $3.5 billion.
Intuitive Surgical, Inc.
ISRG
2025 Q2Healthcare
2d
Revenue Beat
+21%
$2.44 billion
Total revenue for the quarter was $2.44 billion, representing 21% growth over the prior year.
Intuitive Surgical, Inc.
ISRG
2025 Q2Healthcare
2d
Financial Performance Summary
- SP procedures grew 88% year-over-year, and Ion procedures grew 52% to approximately 35,000.
- Gross margin declined to 67.9% from 70% last year due to higher facilities costs, product mix, and tariffs.
- Pro forma operating margin was 39%, and pro forma earnings per share increased 23% to $2.19.
- System placements totaled 395, including 180 da Vinci 5 systems and 23 SP systems, with strong U.S. capital placements but macro challenges in Japan, China, and Europe.
- Da Vinci procedures increased 17% globally, with U.S. growth led by benign general surgery and international growth led by non-urology procedures.
- Second quarter revenue grew 21% to $2.44 billion, driven by strong procedure growth and capital placements.
- GAAP net income was $658 million or $1.81 per share, up from $527 million or $1.46 per share last year.
- Instrument and accessory revenue per procedure remained stable at approximately $1,800.
Danaher Corporation
DHR
2025 Q2Healthcare
3d
Financial Performance Summary
- Biotechnology segment core revenue increased 6%, led by high single-digit growth in bioprocessing and a slight decline in discovery and medical.
- Second quarter sales were $5.9 billion with 1.5% core revenue growth year-over-year.
- Cepheid's non-respiratory molecular diagnostics grew double digits, driven by sexual health, virology, and hospital-acquired infections assays.
- Diagnostics segment core revenue increased 2%, with strong growth outside China, especially in clinical diagnostics and molecular diagnostics non-respiratory revenue.
- Life sciences segment core revenue declined 2.5%, impacted by weak academic and government demand and lower genomics consumables sales.
- Free cash flow was $1.1 billion in the quarter and $2.2 billion in the first half, with a 143% free cash flow to net income conversion ratio year-to-date.
- Adjusted diluted net earnings per share were $1.80, up approximately 5% year-over-year.
- Adjusted operating profit margin was 27.3%, flat year-over-year, driven by volume leverage, product mix, and cost management.
Hold on, more insights are coming